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Abstract
Background: Current Alzheimer’s disease (AD) research initiatives focus on cognitively healthy individuals with
biomarkers that are associated with the development of AD. It is unclear whether biomarker results should be
returned to research participants and what the psychological, behavioral and social effects of disclosure are. This
systematic review therefore examines the psychological, behavioral and social effects of disclosing genetic and
nongenetic AD-related biomarkers to cognitively healthy research participants.
Methods: We performed a systematic literature search in eight scientific databases. Three independent reviewers
screened the identified records and selected relevant articles. Results extracted from the included articles were
aggregated and presented per effect group.
Results: Fourteen studies met the inclusion criteria and were included in the data synthesis. None of the identified studies
examined the effects of disclosing nongenetic biomarkers. All studies but one concerned the disclosure of APOE genotype
and were conducted in the USA. Study populations consisted largely of cognitively healthy first-degree relatives of AD
patients. In this group, disclosure of an increased risk was not associated with anxiety, depression or changes in perceived
risk in relation to family history. Disclosure of an increased risk did lead to an increase in specific test-related distress levels,
health-related behavior changes and long-term care insurance uptake and possibly diminished memory functioning.
Conclusion: In cognitively healthy research participants with a first-degree relative with AD, disclosure of APOE
ε4-positivity does not lead to elevated anxiety and depression levels, but does increase test-related distress and results in
behavior changes concerning insurance and health. We did not find studies reporting the effects of disclosing nongenetic
biomarkers and only one study included people without a family history of AD. Empirical studies on the effects of
disclosing nongenetic biomarkers and of disclosure to persons without a family history of AD are urgently needed.
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February 2016.
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Background
Despite numerous studies conducted in the past two
decades, there are currently no effective disease-modifying
treatments or evidence-based preventive interventions for
Alzheimer’s disease (AD) [1]. Because the pathological
processes underlying the development of clinical AD are
thought to precede the onset of symptoms by years to de-
cades [2–4], previous interventions aiming to prevent AD
may have been initiated too late in the disease process. Re-
cently, research initiatives have therefore turned to people
who are cognitively healthy but supposedly at increased risk
of developing AD on the basis of AD-related biomarkers, in
order to slow down or halt the pathological processes and
prevent the onset of clinical AD symptoms [5, 6]. Examples
of these biomarkers are low amyloid beta 42 and high total
or phosphorylated tau levels in cerebrospinal fluid (CSF)
[7], positive amyloid PET scans [8] and genetic markers
such as the apolipoprotein E (APOE) ε4 genotype [9].
When biomarker examinations are performed in the con-
text of research in people without cognitive complaints, the
question arises of whether the results of these examinations
should actively be returned to study participants.
Whether active disclosure of biomarker status should be
pursued depends on the potential benefit but also potential
harm it may cause to research participants. Of all health
risks people face in life, many people in both Europe and
the USA fear developing AD the most [10, 11]. APOE
genetic testing and nongenetic biomarkers such as brain
amyloid imaging may indicate an increased risk of develop-
ing AD, but do not predict with certainty if and when
someone will develop clinical symptoms [12, 13]; the link
between, for instance, amyloid positivity and cognitive
decline remains particularly elusive [14–16]. Moreover,
because there is no disease-modifying treatment or
prevention strategy available, the possibility to act upon an
increased risk of AD is limited. Based on these consi-
derations, it is plausible that the disclosure of AD-related
biomarkers is associated with an unfavorable balance of
risks and benefits for some people.
Empirical evidence for the effects of AD genetic suscepti-
bility testing has been reviewed previously [17, 18]. Recent
prevention studies do not select individuals solely on the
basis of their genotype but also on the basis of nongenetic
biomarkers [5, 6]. The impact of disclosing these nonge-
netic results, which inform research participants of an
ongoing pathological process in their brains, is potentially
different from the impact of genotype disclosure, which
informs of a risk. The effects of disclosing nongenetic AD
biomarkers to cognitively healthy research participants have
not been reviewed systematically. This systematic review
therefore addresses the following question: what are the
psychological, behavioral and social effects of disclosing
genetic and nongenetic AD-related biomarkers to cogni-
tively healthy research participants?
Methods
This systematic review is reported in accordance with
the Preferred Reporting Items for Systematic Review and
Meta-analyses (PRISMA) statement [19].
Data sources and search strategy
We conducted a systematic literature search in eight
electronic databases on April 28, 2015: Embase, Medline,
PsycINFO, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Cochrane Central Register of
Controlled Trials, Web of Science, PubMed and Google
Scholar. The search strategy was developed in collaboration
with an information specialist from the Erasmus Medical
Centre Medical Library. Search terms used were variations
on the key words: dementia, biological markers, genetic
testing, disease risk, disclosure, and psychological, behav-
ioral and social factors. The full search strategies for all da-
tabases are presented in Additional file 1. Reference lists of
included articles were hand searched for additional studies.
Inclusion and exclusion criteria
Articles were included if they: reported on empirical
evidence; were published in peer-reviewed journals; were
written in English; and reported on actual or hypothet-
ical disclosure. Psychological effects were defined as
effects on emotions, mood and cognition. Behavioral
effects were defined as changes in behavior that were
likely to be caused by the disclosure. Social effects were
defined as effects on individuals in their social context.
Studies were excluded if they concerned participants
who were previously diagnosed with dementia or MCI;
or who had a family history of monogenetic AD. If
multiple articles reported on the same outcome
measures of a single study, the most relevant or
extensive report was selected. Excluded studies and
reasons for exclusion were documented (see Fig. 1).
Study selection
Duplicates were removed after retrieving records from
the search strategy. In the screening phase, titles and
abstracts were independently screened by three
reviewers (SASAB, KT and EMB) for eligibility to the
research question. In the eligibility phase, full-text
articles were assessed by the same three reviewers. In
the case of discrepancy between the reviewers, consen-
sus was reached after discussion.
Data extraction and study quality assessment
Data were extracted from the included studies by one
reviewer (SASAB) using a data extraction form (see
Additional file 2) that was collaboratively designed and
piloted (KT, EMB and ER). We extracted data regarding
the main outcome measures (psychological, behavioral
and social effects), and additional information on study
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design, characteristics and population, content and
method of disclosure, other outcome measures and
funding sources. The risk of bias in quantitative studies
was evaluated with the Cochrane Collaboration’s tool for
assessing risk of bias, insofar as checklist items were
applicable [20]. Qualitative studies were assessed with
the Critical Appraisal Skills Programme checklist for
quality assessment of qualitative research [21]. Studies
with a high risk of bias were excluded from data
synthesis.
Fig. 1 PRISMA flow diagram illustrating process of study selection. In the last step, three studies were excluded due to overlapping data. Fanshawe et
al. [53] was excluded because the behavioral outcomes relevant to our research question are also reported in Chao et al. [22]. Cassidy et al. [54] was
excluded because the psychological effects relevant to our research question are described more extensively in Green et al. [23] Finally, Roberts et al.
[55] was excluded because the psychological effects are described in Green et al. [23] and the behavioral effects in Chao et al. [22] and Zick et al. [24].
AD Alzheimer’s disease, CINAHL Cumulative Index to Nursing and Allied Health Literature
Bemelmans et al. Alzheimer's Research & Therapy  (2016) 8:46 Page 3 of 17
Data synthesis
Reported outcomes were both quantitative and qualitative
in nature and varied widely between studies, so we
composed a metasummary of the reported effects. First,
we extracted data on the effects of disclosure from the
results sections of the eligible studies. Second, we grouped
these effects per outcome measure: psychological, behav-
ioral or social effects.
Results
Study selection and quality assessment
A PRISMA flowchart for the results of the study selection
is shown in Fig. 1. The electronic database searches
generated 2325 unique records. After screening titles and
abstracts, 43 records were evaluated in full text for
eligibility. After this evaluation, 17 articles were deemed
eligible. Three articles were excluded due to overlapping
data, because they reported on the same outcome measures
of a single study as other included articles. Fourteen articles
were eventually identified for data extraction and data
synthesis.
For each article, the main potential types and sources
of bias were identified (see Additional file 3). All 14
articles assessed were considered not to have a high risk
of bias and to be of sufficient quality for inclusion in the
data synthesis of this systematic review [22–35].
Study characteristics of included studies
Of the 14 included studies, two were qualitative studies
(interviews) and 12 were quantitative studies. The qualita-
tive studies included 60 and 79 participants [25, 26]. The
populations of the quantitative studies varied between 76
and 343 participants, with the exception of one article
describing two studies (n = 743) [27] and an online survey
on hypothetical risk disclosure (n = 4036) [28]. In most
studies, follow-up assessments were conducted after
6 weeks, 6 months and 12 months. All 14 studies were
performed in the USA. Of these 14 studies, 11 reported
on data collected in the REVEAL studies. The REVEAL
studies are multicenter randomized controlled trials
examining the effects of (REVEAL I) and different
methods for (REVEAL II and III) APOE genotype disclos-
ure in first-degree relatives (FDRs) of patients with AD. In
the REVEAL I study, participants underwent APOE gen-
etic testing and were randomized to receive either their
genotype and a lifetime AD risk estimate incorporating
this result (the disclosure group) or a risk estimate on the
basis of family history, sex and age only (the nondisclosure
group) [23]. In the REVEAL II study, everyone received
their APOE genotype and participants were randomized
to an extended or condensed disclosure protocol with
either a face-to-face meeting or an information brochure
prior to testing, while both groups had a face-to-face
disclosure session [29]. No articles on the actual disclosure
of nongenetic biomarkers were identified, although the
only article describing hypothetical consequences of
disclosure referred to nongenetic biomarker testing [28].
Whereas most studies examined the difference in out-
come of interest between those receiving ε4-positive and
ε4-negative results, none of them analyzed ε4 heterozy-
gotes and ε4 homozygotes separately. Table 1 presents an
overview of the study characteristics.
Data synthesis
Of the 14 included studies, six reported on psychological
effects, six on behavioral effects and four on social effects
(two studies reported on two types of effects). Results
from all included studies are summarized in Table 2.
Psychological effects
Six studies reported on psychological effects, including
anxiety, depression, test-related distress, coping and
memory functioning [23, 25, 29–32]. In three studies,
anxiety, depression and test-related distress levels were
determined with the Beck Anxiety Inventory (BAI), the
Center for Epidemiological Studies Depression Scale
(CES-D) and the Impact of Event Scale (IES) respectively
[23, 29, 31]. One study evaluated coping by means of a
self-developed questionnaire [30], and another via
interviews [25]. One study assessed objective memory
functioning using the Logical memory subtest of the
Wechsler Memory Scale Revised (WMS-R) and the
Rey-Osterrieth Complex Figure Test (ROCFT), and
assessed subjective memory functioning with the
Metamemory in Adulthood (MIA) questionnaire and the
Memory Functioning Questionnaire (MFQ) [32].
Anxiety
REVEAL I showed that, in FDRs of AD patients, there were
no differences in anxiety levels between APOE ε4-positive
participants, ε4-negative participants and the nondisclosure
group [23, 29]. REVEAL II showed that anxiety levels were
equal among the different disclosure protocols [29]. In both
studies, anxiety levels on the BAI were on average below
the clinical cutoff score of 16 [23, 29]. Telling the testing
result to a friend was associated with a decrease in anxiety
level [31].
Depression
REVEAL I showed no differences in postdisclosure
depression levels between ε4 carriers, ε4-negative partic-
ipants and the nondisclosure group [23]. In REVEAL II,
depression levels were equal in the different disclosure
protocols [29]. In both studies, depression levels on the
CES-D were on average below the clinical cutoff point
of 16 [23, 29]. Twenty-four REVEAL II participants
(9 %) reported depression scores above the clinical cutoff
point 12 months post disclosure, and 21 of these 24 had
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scores below this cutoff score at baseline [29]. Telling
the testing result to a healthcare professional was
associated with a decrease in depression level [31].
Test-related distress
REVEAL I showed that 6 weeks and 6 months, but not
12 months, after disclosure, ε4-positive participants had
higher test related distress levels than ε4-negative partici-
pants. At 6 months, but not 6 weeks and 12 months, after
disclosure, the nondisclosure group had higher test-related
distress than ε4-negative participants [23]. In REVEAL II,
6 weeks and 6 months after disclosure, test-related distress
levels were higher in the condensed protocol group
counseled by a medical doctor compared with the extended
protocol group counseled by a genetic counselor. There
were no differences in distress between the extended and
condensed protocol groups that were both counseled by a
genetic counselor [29]. Postdisclosure distress levels were
on average below the threshold of 20, indicative of
significant distress, in each group [23, 29]. No association
was found between results communication and test-related
distress levels [31].
Coping
One study measured emotional reactions to disclosure 1,
4 and 10 months post disclosure via a self-developed
Table 1 Characteristics of studies included in the systematic review
Authors Year Country Study
name
Study
design
Study
population (n)
Disclosure Assessment
timepoints
Outcome measures
Studies on psychological effects
Romero et al. [30] 2005 USA Cohort 76 APOE
genotype
1 month, 4 months,
10 months
Emotional reactions
Gooding et al. [25] 2006 USA REVEAL QRI Qualitative 60 APOE
genotype
>1 year Coping
Green et al. [23] 2009 USA REVEAL I RCT 162 APOE
genotype
Baseline, 6 weeks,
6 months, 1 year
Anxiety, depression, test-related
distress
Ashida et al. [31] 2010 USA REVEAL II RCT 269 APOE
genotype
Baseline, 6 weeks,
1 year
Relation results communication
and anxiety, depression and
test-related distress
Lineweaver et al. [32] 2014 USA Case–control 144 APOE
genotype
Mean 8.2 months
post disclosure
Objective and subjective memory
functioning
Green et al. [29] 2014 USA REVEAL II RCT 343 APOE
genotype
Baseline, 6 weeks,
6 months, 1 year
Anxiety, depression, distress
Studies on behavioral effects
Zick et al. [24] 2005 USA REVEAL I RCT 162 APOE
genotype
6 weeks, 6 months,
1 year
Insurance uptake
Chao et al. [22] 2008 USA REVEAL I RCT 162 APOE
genotype
1 year Health-related behavior: diet,
physical exercise, medication/
vitamin intake
Vernarelli et al. [33] 2010 USA REVEAL II RCT 272 APOE
genotype
6 weeks Health-related behavior: dietary
supplement intake
Taylor et al. [34] 2010 USA REVEAL II RCT 276 APOE
genotype
Not reported Insurance uptake
Christensen
et al. [27]
2015 USA REVEAL II/III RCT 795 APOE
genotype
6 weeks, 1 year Insurance uptake, health-related
behavior and other behavior
changes
Hypothetical Caselli
et al. [28]
2014 USA Survey 4036 Hypothetical
disclosure
Not applicable Anticipated health-related behavior
and other behavior changes
Studies on social effects
Ashida et al. [35] 2009 USA REVEAL II RCT 271 APOE
genotype
6 weeks Results communication
Ashida et al. [31] 2010 USA REVEAL II RCT 269 APOE
genotype
Base, 6 weeks,
1 year
Relation results communication
and anxiety, depression and
test-related distress
Chilibeck et al. [26] 2011 Canada/USA REVEAL I Qualitative 79 APOE
genotype
Not reported Risk perception in relation to
family history
Hypothetical Caselli
et al. [28]
2014 USA Survey 4036 Hypothetical
disclosure
Not applicable Anticipated results communication
Of the 14 studies included in the systematic review, two report on two types of effects and are taken up twice in this table. Ashida et al. [31] report on both
psychological and social effects, and Caselli et al. [28] report on both behavioral and social effects
APOE apolipoprotein E, RCT randomized controlled trial, REVEAL Risk Evaluation and Education for Alzheimer’s Disease Study
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Table 2 Results of 14 included studies
Authors, year Research question/design Sample (n) Outcome measures Instruments Time points Results
Studies on psychological effects
Romero et al.,
2005 [30]
Participants were asked how they felt
after disclosure of their APOE genotype
76 Self-developed
questionnaire
ε4-negative group ε4-positive group
Feeling depressed 1 month 0/49 8/27
4 months 0/49 5/27
10 months 0/47 4/27
Feeling worried 1 month 0/49 6/27
4 months 0/49 3/27
10 months 0/47 3/27
Feeling relieved 1 month 36/49 4/27
4 months 30/49 5/27
10 months 34/47 3/27
Gooding et al.,
2006 (REVEAL
QRI) [25]
56 participants in the REVEAL I study and
four individuals who declined participation
were interviewed about their reaction to
the received results (either risk estimate
and genotype or risk estimate only)
60a Coping: Interviews >12 months ε4-positive group Other (ε4-, ND, not
REVEAL-ptc)
Relief 4/17 (24 %) were relieved:
“Even with the ε4 allele,
their risk was not as high
as they had previously
anticipated”
25/43 felt relievedb
Worry Six participants, all ε4+,
expressed greater
concern about their AD
risk after disclosure,
describing their results as
“depressing”, “frightening”
and “disappointing”
14/39 who participated in
REVEAL were neither
relieved nor worried
Neither 7/17 were neither
relieved nor worried.
They related their “lack of
emotion to the lack of
predictability of the APOE
test and the feeling that
it only confirmed what
they had already come to
accept as their risk for AD”
Green et al.,
2009 [23]
(REVEAL I)
Participants were randomly assigned to
receive their APOE genotype and a risk
estimate (ε4-positive and ε4-negative
group) or a risk estimate only (no
disclosure group)
162 ε4-positive group ε4-negative group No disclosure
group
Anxiety BAI (0–63) 6 weeks 5.2 (0.7)c 4.5 (0.6) 4.4 (0.7)c
6 months 4.6 (0.6) 3.9 (0.6) 4.6 (0.6)
12 months 4.4 (0.6) 4.2 (0.6) 4.2 (0.6)
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Table 2 Results of 14 included studies (Continued)
Depression CES-D (0–60) 6 weeks 9.0 (1.0) 8.5 (0.9) 9.3 (1.0)
6 months 9.6 (1.0) 8.9 (1.0) 8.7 (1.0)
12 months 8.3 (0.9) 8.5 (0.9) 8.0 (0.9)
Distress IES (0–75) 6 weeks 9.4 (1.3)d 5.2 (1.3) 6.7 (1.4)
6 months 8.6 (1.2)d 4.2 (1.2) 8.9 (1.3)e
12 months 8.5 (1.3) 5.1 (1.2) 7.7 (1.5)
Ashida et al.,
2010 (REVEAL II)
[31]
Participants in the REVEAL II study all
received their APOE genotype, and were
randomly assigned to either an extended
or condensed disclosure protocol
269 Effect of results
communication on
psychological well-being:
“Have you told
anyone your APOE
genetic test result?
If so, who?”
6 weeks 62.1 % told a family member, 52 % their spouse or
significant other, 37.5 % a friend and 14.9 % a health
professional
Anxiety BAI 12 months Telling the result to a friend was associated with a
decrease in BAI at 12 months (regression coefficient
b = –0.17, p < 0.01)
Depression CES-D Telling the result to a healthcare professional with a
decrease in CES-D at 12 months (regression coefficient
b = –0.10, p < 0.05)
Distress IGT-ADf (0–60) There was no association between results communication
and IGT-AD levels of distress
24 participants (9 %) reported scores > than the clinical
cutoff point of 16 on the CES-D at 12 months, and 21
of these 24 had scores < the cutoff at baseline
Lineweaver
et al., 2014 [32]
A group of research participants who
were informed about their APOE
genotype was compared with a matched
group who did not receive their genotype
on objective and subjective memory
functioning
144 Objective memory
functioning Subjective
memory functioning
Logical memory
subtest
Mean
8.2 months
ε4-positive
uninformed
ε4-positive
informed
ε4-negative
uninformed
ε4-negative
informed
immediate recall 31.9 (8.5)h 22.9 (7.8) 28.4 (7.8) 25.6 (5.9)
delayed recall
Wechsler Memory
Scale Revised (0–50)g
28.1 (9.3)h 17.7 (7.9) 24.3 (9.6) 20.6 (6.9)
Immediate recall
delayed recall on
Rey–Osterrieth
Complex Figure
test (0–20)
9.7 (2.7) 10.6 (2.6) 9.3 (3.7) 9.7 (3.1)
9.0 (3.1) 10.1 (2.4) 9.0 (4.0) 9.9 (2.8)
Metamemory in
Adulthood
Questionnaire:
Capacity subscale
Change over time
subscale (15 items
5-point Likert scale)
31.2 (5.2)i 28.0 (6.4) 27.8 (6.5)j 30.5 (4.7)
17.0 (5.4) 16.9 (5.5) 15.9 (4.9) 16.7 (4.1)
Memory Functioning
Questionnaire:
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Table 2 Results of 14 included studies (Continued)
Retrospective
functioning
18.3 (5.8) 15.9 (4.7) 14.3 (4.1)k 16.7 (4.7)
Frequency of
forgetting
90.5 (14.7) 83.4 (13.3) 84.5 (17.0) 88.9 (13.4)
Forgetting when
reading
54.9 (8.4) 50.7 (9.3) 50.5 (13.1)k 55.5 (8.8)
Forgetting past
events
19.2 (4.6) 18.3 (4.3) 18.1 (4.9) 19.9 (4.5)
Mnemonics usage
(46 items with
7-point Likert scale)
23.1 (11.4) 20.3 (7.4) 22.8 (9.5) 25.1 (8.4)
Green et al.,
2014 (REVEAL II)
[29]
Participants were randomly assigned to
receive their APOE genotype in an
extended protocol (SP-GC), a condensed
protocol with a genetic counselor (CP-GC)
or medical doctor (CP-MD). Aim was to
assess whether the condensed protocols
were equal (= mean score on any of the
scales not more than 5 points higher) to
the extended protocol
343 SP-GC CP-GC CP-MD
Anxiety BAI (0–63) 6 weeks 2.6 (0.5)c 3.6 (0.5) 4.3 (0.5)
6 months 3.2 (0.5) 3.1 (0.5) 4.4 (0.5)
12 months 3.0 (0.5) 3.7 (0.5) 3.9 (0.5)
Depression CES-D (0–60) 6 weeks 5.7 (0.7) 5.8 (0.7) 8.1 (0.7)
6 months 6.3 (0.7) 5.8 (0.7) 8.1 (0.7)
12 months 6.2 (0.6) 5.6 (0.6) 6.9 (0.6)
Distress IES (0–75) 6 weeks 2.8 (0.9) 5.1 (0.9) 8.2 (0.9)l
6 months 3.9 (0.9) 4.0 (0.9) 7.0 (0.9)l
12 months 3.4 (0.8) 3.3 (0.8) 5.5 (0.8)
Studies on behavioral effects
Zick et al., 2005
(REVEAL I) [24]
REVEAL I, see Green et al., 2009 [23] 162 Insurance uptake Questionnaires on
actual change in
6 weeks,
6 months,
12 months
ε4-positive group ε4-negative group No disclosure
group
Health insurance 12.5 5.56 6.52
Life insurance 2.08 7.41 6.52
Disability insurance 4.17 3.70 4.35
LTC insurance (%) 16.7m 1.85 4.35
Planned change in
Health insurance 25.0 13.0 23.9
Life insurance 16.67 5.56 4.35
Disability insurance 18.8 7.41 8.70
LTC insurance (%) 45.8m 22.2 32.6
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Table 2 Results of 14 included studies (Continued)
OR for actual
change in LTC
insurance ε4+
compared
with ND: 5.76
(p < 0.1)
Taylor et al.,
2010 (REVEAL II)
[34]
REVEAL II, see Green et al., 2014 [29] 276 LTC insurance Not reported Not
reported
Two ε3 traits ≥ one ε4 trait At least one ε2
trait, no ε4 trait
OR of actual or planned
change
1.00 2.31 (95 % CI 1.11–4.81) 1.55 (95 % CI
0.43–5.60)
Absolute probability of
changing LTC insurance
0.087 0.237 0.149
Chao et al.,
2008 (REVEAL I)
[22]
REVEAL I, see Green et al., 2009 [23] 162 Health-related behavior
changes
Yes/no questions
about changes in:
12 months ε4-positive group ε4-negative group no disclosure
group
Any behavior
specific to AD
prevention
52n 24 30
Medications/vitamins 40 20 28
Diet 20 11 7
Exercise
(% endorsing)
8 4 5
OR of any
behavior change
ε4+ vs ε4–
group: 2.73
(95 % CI
1.14–6.54)
Vernarelli et al.,
2010 (REVEAL II)
[33]
REVEAL II, see Green et al., 2014 [29] 272 Changes in supplement
use
Yes/no questions
with free-text field
on changes in:
overall diet use of
dietary supplements
exercise (ORs)
6 weeks ε4-positive group ε4-negative group
1.56 (95 % CI 0.80–3.02) 1.00
4.75 (p < 0.0001)
(95 % CI 2.23–10.10)
1.00
1.85 (95 % CI 0.96–3.57) 1.00
Of 45 participants reporting
a change in supplement use,
32 (71.1 %) were ε4+
(p < 0.0001). Of these 45, 38
were in the condensed
protocol (84.4 %) and seven
in the extended (15.5 %)
(p = 0.006)
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Table 2 Results of 14 included studies (Continued)
Christensen
et al., 2015
(REVEAL II/III)
[27]
Secondary analyses were performed on
data from the REVEAL II and III study. For
REVEAL II, see Green et al., 2014 [29]. In
the REVEAL III study, in-person and phone
disclosure, and giving AD genetic info
only and pleiotropic info were compared
795 Associations between
recruitment status
(actively recruited (ARP)
or self-referred (SRP)) and
behavior changes and
advance planning
Yes/no questions on
actual and planned
changes in:
6 weeks,
12 months
Self-referred participants were more likely than ARPs to
report changes to exercise at 12 months (35 % vs 25 %,
p = 0.032). No other differences between recruitment
cohorts were noted on changes or plans to change
health behaviors
Health behavior:
Mental activities Diet
Exercise Dietary
supplements
Medications
Secondary analyses showed that the impact of genetic risk
status on certain behavior changes differed by recruitment
cohort. ε4-positive participants were more likely than
ε4-negative participants to report changes at 6 weeks to
mental activities and diet, but only if they had self-referred
to the study, although only differences in changes to
mental activities persisted through the 12-month follow-up
Advance planning:
LTC insurance
Retirement plans
No direct associations with self-referral were observed on
either LTC insurance coverage or retirement plans. An
interaction effect was observed (p = 0.005): self-referred
ε4-positive participants were more likely than ε4-negative
participants to report intentions to change LTC coverage,
but no differences were noted among ARPs
No associations were noted on retirement plans, except
greater intentions to change among ε4-positive participants
compared with ε4-negative participants, regardless of
recruitment cohort (p < 0.001)
Studies on hypothetical disclosure
Caselli et al.,
2014 [28]
Members of an online community for
people interested in AD prevention
research completed a survey on their
interest in and anticipated reaction to
hypothetical genetic and biomarker
testing and disclosure
4036 Results communication Multiple-choice
questions
Not
applicable
If APOE ε4 positive, you
would tell:
(%)
Physician 79.4
Spouse 92.3
Siblings 84.6
Children 81.7
Friends 53
Lawyer 60
If biomarker evidence of AD,
you would tell:
Spouse 92.2
Siblings 80.6
Children 75.9
Friends 46.5
Lawyer 53.8
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Table 2 Results of 14 included studies (Continued)
Behavior changes If APOE ε4 positive, you
would:
(%)
Begin a healthier lifestyle 90.5
Get LTC insurance 76.3
Spend all your money
forpleasure
18.4
Seriously consider suicide 11.6
If biomarker evidence of AD,
you would:
Begin a healthier lifestyle 91
Get LTC insurance 76.6
Spend all your money for
pleasure
18.7
Seriously consider suicide 10.2
Studies on social effects
Ashida et al.,
2009 (REVEAL II)
[35]
REVEAL II, see Green et al., 2014 [29] 271 Communication of APOE
genetic test result
“Have you told
anyone your APOE
genetic test result?
If so, who?”
6 weeks Person Frequency (%)
Anyone 81.5
Family member 63.8
Spouse/significant other 50.9
Friends 34.7
Health professional 12.2
OR of results communication
to health professional in
condensed vs extended
protocol 5.19 (95 % CI
1.50–17.89, p < 0.01)
Chilibeck et al.,
2011 (REVEAL I)
[26]
Interviews were conducted with
participants from REVEAL I and with
FDRs of AD patients who did not
undergo genetic testing
79 (REVEAL
participants)
and 40
(non-REVEAL)
Effect of personalized
genetic information on
conceptualization of
personal risk, family
health and familial
relationships
Open-ended
interviews
Not
reported
Drawn from the report: when genetic information
corresponds with previous beliefs about risk and
inheritance, people emphasize how the information
provided by genetic testing is “not new” to them but
only confirms what they already knew or at least
suspected. Yet risk predictions generated by genetic
technologies sometimes conflict with those rooted in
everyday beliefs about heredity. The visible evidence
of risk provided by family history is often more
compelling than that based on a genetic test
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Table 2 Results of 14 included studies (Continued)
Conclusion: “The genetic risk information given to
subjects in the REVEAL trial is interpreted through a
process of ‘familiarization’ in which risk estimates are
absorbed into and embedded within pre-existing
beliefs about who in the family will succumb to AD.
These narratives resemble those of individuals from AD
families who have not been genetically tested, strongly
suggesting that ideas about embodied risk for AD in
families are not dramatically changed as a result of
genetic testing.”
Of the 14 studies included in the systematic review, two report on two types of effects. In this table they are taken up only once. Ashida et al. [31] report on both psychological and social effects; results from this
study are to be found among the studies on psychological effects in this table. Caselli et al. [28] report on both behavioral and social effects; results from this study are to be found among the studies on behavioral
effects in this table
AD Alzheimer’s disease, APOE apolipoprotein E, ARP actively recruited participants, BAI Beck Anxiety Inventory, CES-D Center for Epidemiological Studies Depression Scale, CI confidence interval, CP-GC condensed
protocol genetic counselor, CP-MD condensed protocol medical doctor, FDR first-degree relative, I informed, IES Impact of Event Scale, IGT-AD Impact of Genetic Testing for Alzheimer’s Disease, LTC long-term care, ND
no-disclosure group, OR odds ratio, RCT randomized controlled trial, REVEAL Risk Evaluation and Education for Alzheimer’s Disease Study, SP-GC standard protocol genetic counselor, SRP self-referred participants,
UI uninformed
aAlthough the question of one’s response to the results is not applicable to those who declined participation in REVEAL (n = 4), the original article does not leave those individuals out of this part of the results section
bFifteen participants were in the no-disclosure group in REVEAL and received a lifetime risk estimate only. This group is not analyzed separately in their reaction to the results
cScores are mean values ± SE
dDifference ε4+ vs ε4– is significant at 6 weeks and 6 months (p < 0.05)
eDifference ND vs ε4– is significant at 6 months (p < 0.05)
fIGT-AD based on the Multidimensional Impact of Cancer Risk Assessment Questionnaire
gOn all memory scales, higher scores indicate better objective/subjective memory functioning. Scores are mean values ± SD
hp ≤ 0.001 ε4+ UI vs ε4+ I
ip < 0.05 ε4+ UI vs ε4+ I
jp < 0.05 ε4–UI vs ε4– I
kp < 0.05 ε4–UI vs ε4– I
lNoninferiority of CP-MD vs SP-GC could not be confirmed for test-related distress at 6 weeks and 6 months
mp < 0.05 ε4+ vs ε4–
nε4+ vs ε4–, p = 0.003; ε4+ vs ND, p = 0.03
Bem
elm
ans
et
al.A
lzheim
er's
Research
&
Therapy
 (2016) 8:46 
Page
12
of
17
questionnaire: 61–73 % of ε4-negative participants and
11–19 % of ε4-positive participants felt relieved after
disclosure. Of the ε4-positive participants, 15–30 % felt
depressed and 11–22 % felt worried after disclosure,
compared with no individuals in the ε4-negative group
[30]. Of the REVEAL participants interviewed in the RE-
VEAL Qualitative Research Initiative, 24 % of ε4-positive
participants were relieved after receiving results, versus
58 % of a group consisting of both ε4-negative partici-
pants and individuals from the nondisclosure group.
Thirty-five percent of ε4-positive participants expressed
greater concern about their risk for AD, describing their
results as “depressing”, “frightening” and “disappointing”,
compared with no one in the other group. Forty-one
percent of ε4-positive participants were neither relieved
nor worried. In the group consisting of ε4-negative par-
ticipants and people from the nondisclosure group, 36 %
of 39 participants felt neither relieved nor worried after
learning their results [25].
Memory functioning
One study examined the effects of disclosure on objective
and subjective memory functioning. Participants who
were aware of being ε4-negative rated multiple aspects of
their own memory functioning higher on the MIA and
the MFQ than ε4-negative participants who did not know
their genotype. Participants who knew they were ε4-posi-
tive rated their memory functioning on the capacity sub-
scale of the MIA lower, and performed worse on a logical
memory subtest of the WMS-R than ε4-positive partici-
pants who were not informed [32].
Behavioral effects
Six studies assessed one or more behavioral effects, includ-
ing changes in insurance uptake, health-related behavior
and other behavior [22, 24, 27, 28, 33, 34]. Five of those
were part of the REVEAL studies [22, 24, 27, 33, 34]. Three
studies examined actual and planned changes in insurance
uptake within 1 year after disclosure via self-report
questionnaires [24, 27, 34]. Health-related behavior changes
were assessed by means of yes/no questions on specific
behavior changes in three studies [22, 27, 33], and by asking
“If APOE ε4-positive/biomarker evidence of AD, you
would” followed by several options in a study on hypothet-
ical disclosure [28]. Two studies measured other behavioral
effects, one via yes/no questions on specific actual or
planned behavior changes [27] and one via the aforemen-
tioned question on hypothetical disclosure [28].
Insurance uptake
In REVEAL I, in the first year following disclosure, 16.7 %
of ε4-positive participants changed long-term care (LTC)
insurance, versus 1.9 % of ε4-negative participants and
4.4 % of the nondisclosure group. In addition, 45.8 % of
ε4-positive participants planned to change LTC insurance,
versus 22.2 % of ε4-negative participants and 32.6 % of the
nondisclosure group. No differences were found in
changes to health, life or disability insurance uptake [24].
Data from REVEAL II show that ε4-positive participants
are 2.3 times more likely to report an actual or planned
change to LTC insurance than people with two ε3 alleles
[34]. Secondary analyses of REVEAL II data indicate that
the intention to change LTC coverage among ε4-positive
participants is limited to those who had self-referred to
the study [27]. In a study of the hypothetical reaction to
disclosure, 76 % would get LTC insurance if APOE
ε4-positive and 77 % in the case of (nongenetic) biomarker
evidence of AD [28].
Health behavior
REVEAL I showed that 12 months after disclosure, ε4-posi-
tive participants reported changes in any one of the do-
mains of diet, physical exercise and medication or vitamin
intake, more often (52 %) than ε4-negative participants
(24 %) or the nondisclosure group (30 %). Within each
domain, there were no significant differences between the
groups [22]. In REVEAL II, 6 weeks after disclosure,
ε4-positive participants were almost five times more likely
to report changes to dietary supplement intake, but not to
diet or physical exercise, than ε4-negative participants [33].
Secondary analyses of REVEAL II pointed out that ε4-posi-
tive participants were more likely to have changed diet
6 weeks after disclosure, mental activities 6 weeks after dis-
closure and 12 months after disclosure and medication in-
take 12 months after disclosure than ε4-negative
participants, but only if they had self-referred to the study
[27]. In a hypothetical disclosure scenario, 90.5 % of respon-
dents would adopt a healthier life style if APOE ε4-positive
and 91 % in the case of having (nongenetic) biomarker evi-
dence of AD [28].
Other behavioral effects
Two studies reported on other, planned, behavioral effects
[27, 28]. The REVEAL II study found greater intentions to
change retirement plans among ε4-positive participants
than ε4-negative participants [27]. In the study on
hypothetical disclosure, if people would be found to be
ε4-positive or to have nongenetic biomarker evidence of
AD, 18.4 and 18.7 % of respondents would spend all their
money for pleasure and 11.6 and 10.2 % agreed to the
statement that they would seriously consider suicide [28].
Social effects
Four studies reported on social effects, namely the
communication of results and the perception of risk in
relation to family history [26, 28, 31, 35]. Three studies
examined results communication; two by asking partici-
pants in written questionnaires “Have you told anyone
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your result? If so, who?” [31, 35]; and one by asking
hypothetically “If APOE ε4-positive/biomarker evidence
of AD, you would tell …” followed by several options
[28]. The results of one of these studies, on the effects
communication has on anxiety, depression and test-
related distress, are described in the psychological effects
section [31]. Risk perception in relation to family history
was studied in open-ended interviews [26].
Results communication
In REVEAL II, 81.5 % of participants told at least one
person their result; 63.8 % told a family member, 50.9 %
their spouse or significant other, 34.7 % a friend and
12.2 % a health professional [35]. In a hypothetical sce-
nario of being APOE ε4-positive, 79.4 % of respondents
would tell their physician, 92.3 % their spouse, 84.6 % a
sibling, 81.7 % their children, 53 % friends and 60 %
their lawyer. In case of having (nongenetic) biomarker
evidence of AD, 92.2 % would tell their spouse, 80.6 % a
sibling, 75.9 % their children, 46.5 % friends and 53.8 %
their lawyer [28].
Perception
In one study, interviews were conducted with two groups
of FDRs of AD patients; the first group consisted of
individuals who had undergone genetic testing (REVEAL
participants), and the second contained people who had
not received information on the genetics of AD [26]. Ideas
on the causation of AD and personal risk of developing AD
were found to be similar in these groups, suggesting that
receiving information on the genetics of AD and undergo-
ing genetic testing for AD does not strongly alter these
ideas. The REVEAL participants included in this study
considered genetic test results that corresponded with prior
beliefs regarding their risk of AD based on family history to
be “not new”, whereas if test results conflicted with prior
beliefs then family history was often more compelling in
participants’ self-perception of risk. Some participants
turned out APOE ε4-negative but continued to feel their
actual risk was higher than the risk they learned, because of
their family history.
Discussion
In this review on the psychological, behavioral and social
effects of disclosing genetic and nongenetic AD biomarkers
to cognitively healthy research participants we found that
disclosing an APOE ε4 genotype to cognitively healthy
FDRs of AD patients in a controlled research context does
not appear to result in anxiety or depression [23, 29]. Being
informed of ε4-positivity does lead to an increase in test-
related distress, LTC insurance uptake and health-related
behavior changes when compared with the disclosure of
ε4-negativity, and possibly influences memory functioning
[22–24, 29, 32–34]. In addition, in people with a family
history of AD, disclosure of APOE genotype does not radic-
ally alter beliefs regarding the causation of AD and personal
risk [26]. No studies reporting on the impact of disclosure
of nongenetic biomarkers were identified. Only a single
study on hypothetical disclosure referred to both genetic
and nongenetic biomarkers.
Based on these studies, disclosure of APOE genotype
is often considered to result in relief in case of low risk
and to be “safe” in case of high risk [18, 36]. Whereas
the first part of this conclusion seems justified [37, 38],
several remarks can be made regarding the second.
First, in every study in which genotype was disclosed
(except for [32]), participants were FDRs of AD patients.
In these individuals the effects of genotype disclosure
can be expected to be relatively small, because most may
already suspect to be at increased risk on the basis of
their family history. Interviews with participants with a
FDR with AD show that those with an ε4 allele are
indeed not surprised, whereas those without an ε4 allele
sometimes find it hard to believe [26]. Hence, results
from this particular study population cannot simply be
generalized to other groups. In research participants
who do not have a family history of AD or who are un-
aware of the increased risk that is associated with being
a FDR of an AD patient, the impact of APOE genotype
disclosure may be more substantial. The results of the
REVEAL III study, in which a quarter of the participants
were not FDRs of AD patients, are expected to show the
impact of disclosure in this group and are eagerly
awaited [27].
Second, although disclosure does not on average result in
more depression, careful interpretation of these results is
warranted. In one of the studies, 24 participants (9 %)
scored above the clinical cutoff score for depression
12 months after disclosure, while 21 of them scored below
this threshold at baseline [31]. In another study, between 15
and 30 % of participants agreed to a statement of feeling
depressed after disclosure of an increased AD risk, whereas
none of the low-risk individuals did so [30]. It must be
noted that these were all participants who underwent
psychological screening prior to inclusion, and that it is cur-
rently unknown whether the impact of receiving biomarker
results is different in people who already experience
psychological problems at baseline. These findings suggest
that while the impact of disclosure may be low on average,
there may be negative consequences for a subset of partici-
pants. Although this subset is relatively small, because AD
research initiatives aim to recruit large numbers of research
participants, a considerable number of people could be
negatively affected [5, 6].
Third, disclosure of an increased genetic risk may
negatively influence subjective and objective memory
functioning in people without cognitive impairment
prior to disclosure [32]. Risk disclosure may thus not
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only lead to a perceived diminishment in memory
functioning, but also to a measurable diminishment. A
similar effect is known from drug trials in which
information on side effects can induce those very
symptoms, a phenomenon referred to as the “nocebo” or
negative placebo effect. This is supposedly the result of
negative expectations regarding the side effects of the
intervention [39]. Labeling someone as being at high risk
of developing AD may in the same way create negative
expectations of one’s own memory functioning, resulting
in actual diminished functioning [40].
Fourth, the reported behavior changes after learning one
carries an APOE ε4 allele are not merely positive. On the
one hand, the increase in LTC insurance uptake reported
by ε4-positive participants can be considered a benefit
because it corresponds to an important reason why people
want to know their AD risk, namely to plan for the future
and arrange personal affairs [41–43]. At the same time,
fear of insurance discrimination is among the main rea-
sons why people do not want genetic susceptibility testing
[41, 42]. Because the increase in LTC insurance uptake by
those at increased risk of developing AD indicates a
potential for adverse selection [24, 34], which insurers
may seek to prevent by charging at-risk individuals more
or even refusing them as clients, this fear is not far-
fetched; for instance, current US legislation to protect citi-
zens against insurance discrimination on the basis of gen-
etic information does not apply to LTC and disability
insurance [44]. Although seemingly innocent, increasing
dietary supplement intake may also have negative
consequences. It may give people a false sense of control
over their situation, as the most frequently taken supple-
ment after genotype disclosure, vitamin E [33], does not
help in preventing AD [45]. In fact, it may even have a
paradoxically negative effect on cognition in some [46]
and has significant potential side effects [47].
The conclusion that disclosing increased genetic risk
of AD to healthy research participants is “safe” [18, 36]
thus deserves some nuance. The current findings cannot
be extrapolated to nongenetic biomarkers because there
are potentially important differences [48]. In particular,
the presence of nongenetic biomarkers compatible with
an “AD profile”, such as a positive amyloid PET scan, is
increasingly considered not only as indicative of
pathological processes that may eventually lead to the
development of AD, but as defining the disease itself,
even in the absence of symptoms. In recent research
criteria, persons with AD-related nongenetic biomarkers
are labeled as being in a “preclinical stage of Alzheimer's
disease” [4, 49] suggestive of the inevitable onset of
dementia in the future. Although the one study on hypo-
thetical disclosure shows similar envisioned reactions to
receiving genetic and nongenetic AD biomarker results,
it also shows that one-third of the respondents do not
associate (nongenetic) biomarker evidence of AD with
either the presence of AD or an increased risk of devel-
oping AD [28]. If people receive nongenetic biomarker
results in a research context in which they learn that
nongenetic biomarkers are not merely risk factors but
reflect an ongoing biological process, their response may
strongly differ from their reaction to genetic biomarkers.
Limitations of this systematic review
The present systematic review does not consider risk per-
ception as a psychological effect in itself and because of that
the search strategy does not cover this aspect. Gaining a full
understanding of the effects of AD biomarker disclosure
will need to involve further study of how individual risk
perception mediates the information disclosed and psycho-
logical or behavioral effects. How one perceives one’s risk
may not always be in line with the risk estimate one re-
ceived and/or recalls [50]. In that case, instead of mediating,
the (wrongly) perceived risk may directly cause psy-
chological effects. Finally, risk perception understood in
relation to self-perception is an outcome of interest in itself
too. Do participants to whom risk is disclosed see
themselves the same as before? Or as people who are
destined to develop AD? Or maybe even as people who are
already ill, waiting for symptoms to manifest [51]?
A second limitation concerns the risk of bias in
individual studies. Although we considered all eligible
studies of sufficient quality and none as having a high
risk of bias, limited bias could have influenced the
results. The included studies do not explicitly mention
having excluded people with subjective cognitive com-
plaints. An uneven distribution of people with cognitive
complaints over the ε4-positive and ε4-negative groups
could have interacted with and obscured the relation be-
tween the disclosed result and the impact of disclosure.
The results of those studies particularly prone to bias
(e.g., because of a nonrandomized study design) were
and should be interpreted with caution.
Finally, the identified studies had limited heterogen-
eity, both with regard to the type of biomarker disclosed
(APOE genotype only) and with regard to the study
population (all US cultural background, mostly FDRs of
AD patients and only people without psychological
complaints at baseline). Because studies on the public
interest in predictive genetic testing for AD show
significant cultural differences [52], the effects of
disclosure may also differ across cultures and settings.
Furthermore, because people with moderate to high
levels of anxiety, depression and distress at baseline were
excluded from the identified studies, the effect of
disclosure on these potentially more vulnerable people,
is at present unknown. Therefore, one should be careful
in extrapolating the results of these studies to other
settings and research participant groups.
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Conclusions
In the context of research, the disclosure of an APOE ε4
genotype overall has no major psychological, behavioral
and social impact on cognitively healthy FDRs of
patients with AD. The disclosure does, however, lead to
elevated test-related distress, depressive symptoms in
some, increased uptake of LTC insurance and changes in
health-related behavior such as dietary supplement in-
take. Furthermore, it may affect subjective and objective
memory functioning. The impact of disclosing other,
nongenetic, biomarkers such as amyloid PET scans or
CSF abnormalities is currently unknown. Knowledge of
this impact is needed for research projects to decide on
whether, when and how biomarker results should be
disclosed. Moreover, it will enable institutional review
boards to make informed judgments of the risk–benefit
ratios in proposed studies, and potential participants in
choosing whether or not to participate. Therefore, before
engaging in large-scale research projects disclosing
biomarkers other than APOE genotype to persons
without a family history of AD, research on the psycho-
logical, behavioral and social impact of this disclosure is
indispensable.
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